ARMPArmata Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Armata Pharmaceuticals, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARMP본 종목 | $155M#5 | — | — | — | — | -818.8%#9 | — | — | — | — | 41.5%#2 | 0.1%#1 |
| VYGR | $188M#1 | — | 1.2x#2 | 4.6x#1 | -49.5%#2 | -84.2%#7 | -326.6%#2 | -77.6%#4 | — | — | — | — |
| DTIL | $179M#2 | — | 3.9x#6 | 5.2x#2 | -50.1%#3 | -738.0%#8 | -152.2%#1 | -101.0%#5 | — | — | 42.0%#1 | — |
| OTLK | $166M#3 | — | — | 117.3x#5 | — | 17.2%#3 | -4744.3%#4 | — | -12.8%#1 | — | — | — |
| HUMA | $158M#4 | — | 5.1x#7 | 77.6x#4 | — | 72.5%#1 | -5306.0%#5 | -130.6%#7 | — | — | — | — |
| TNYA | $148M#6 | — | 2.1x#3 | — | — | 18.5%#2 | — | -130.5%#6 | — | — | — | — |
| NMRA | $145M#7 | — | 3.2x#4 | — | — | -2.8%#5 | — | 532.2%#1 | -594.0%#2 | — | — | — |
| LENZ | $129M#8 | — | 0.6x#1 | 6.8x#3 | — | -65.0%#6 | -477.5%#3 | -37.5%#3 | — | — | — | — |
| CRDF | $101M#9 | — | 3.8x#5 | 170.5x#6 | -13.2%#1 | -0.9%#4 | -8256.3%#6 | -0.2%#2 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice